Ocular Therapeutix
OCUL

Ocular Therapeutix (OCUL) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
UBSInitiated CoverageBuy$14.00Oct 12, 2026
Chardan CapitalMaintainedBuy$23.00Oct 2, 2026
NeedhamMaintainedBuy$18.00Sep 29, 2026
HC Wainwright & Co.MaintainedBuy$25.00Sep 16, 2026
Chardan CapitalMaintainedBuy$23.00Sep 16, 2026
Chardan CapitalMaintainedBuy$23.00Aug 4, 2026
Chardan CapitalMaintainedBuy$23.00 from $21.00Jun 25, 2026
HC Wainwright & Co.MaintainedBuy$25.00 from $21.00Jun 18, 2026
BairdMaintainedOutperform$30.00 from $24.00Jun 18, 2026
RBC CapitalMaintainedOutperform$30.00May 6, 2026
NeedhamMaintainedBuy$18.00May 5, 2026
HC Wainwright & Co.MaintainedBuy$21.00Apr 13, 2026
Clear StreetMaintainedBuy$28.00 from $21.00Mar 3, 2026
NeedhamMaintainedBuy$18.00 from $20.00Feb 20, 2026
Chardan CapitalMaintainedBuy$21.00Feb 18, 2026
Chardan CapitalMaintainedBuy$21.00Dec 9, 2025
HC Wainwright & Co.MaintainedBuy$21.00 from $19.00Dec 8, 2025
NeedhamMaintainedBuy$20.00Dec 8, 2025
HC Wainwright & Co.MaintainedBuy$19.00Nov 25, 2025
Chardan CapitalMaintainedBuy$21.00Nov 5, 2025

Frequently asked questions

  • What is the latest analyst rating on OCUL?

    On Oct 12, 2026, UBS initiated coverage of Ocular Therapeutix at Buy with a price target of $14.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.